{"id":501465,"date":"2021-06-07T16:11:36","date_gmt":"2021-06-07T20:11:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/"},"modified":"2021-06-07T16:11:36","modified_gmt":"2021-06-07T20:11:36","slug":"novavax-to-participate-in-panel-at-bio-digital-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/","title":{"rendered":"Novavax to Participate in Panel at BIO Digital 2021"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n GAITHERSBURG, Md.<\/span>, June 7, 2021<\/span> \/PRNewswire\/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck<\/span>, President and Chief Executive Officer, will participate in a panel discussion<\/a> at the BIO International Convention 2021 on June 14<\/span>. BIO\u00a0Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11<\/span> and June 14-18<\/span>. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.<\/p>\n

\n

\n
\n \"Stanley
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n Panel details are as follows: <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n
\n Date:<\/b>\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Monday, June 14, 2021<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Time:<\/b>\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n 3:00 p.m. \u2013 3:45 p.m. Eastern Time (ET)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Title:\u00a0<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Global Pandemic Preparedness \u2013 It Takes a Globe…. <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Moderator<\/b>:\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Phyllis Arthur<\/b>, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Panelists<\/b>:\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Stanley C. Erck<\/b>, President and Chief Executive Officer, Novavax<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Amanda Glassman<\/b>, Executive Vice President, Chief Executive Officer, CGD Europe and Senior Fellow, Center for Global Development<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Richard Hatchett<\/b>, M.D., Chief Executive Officer, Coalition for Epidemic Preparedness<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Rajeev Venkayya<\/b>, M.D., President, Global Vaccine Business Unit, Takeda Pharmaceuticals<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

For more information or to register for the meeting, visit: https:\/\/www.bio.org\/events\/bio-digital\/registration<\/a>.<\/p>\n

\n About NVX-CoV2373
<\/b>NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using\u00a0Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with\u00a0Novavax’ patented saponin-based Matrix-M\u2122 to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1\/2 clinical testing.<\/p>\n

NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the\u00a0U.K.\u00a0that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7\/501Y.V1 variant and 89.7% overall; and the PREVENT-19 trial in the\u00a0U.S.\u00a0and\u00a0Mexico\u00a0that began in\u00a0December 2020. It is also being tested in two ongoing Phase 2 studies that began in\u00a0August 2020: A Phase 2b<\/span> trial in\u00a0South Africa\u00a0that demonstrated 48.6% efficacy against a newly emerging escape variant first described in\u00a0South Africa, and a Phase 1\/2 continuation in the\u00a0U.S.\u00a0and\u00a0Australia.<\/p>\n

NVX-CoV2373 is stored and stable at 2\u00b0- 8\u00b0C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.<\/p>\n

\n About Matrix-M\u2122 Adjuvant
<\/b>Novavax’ patented saponin-based Matrix-M\u2122 adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.<\/p>\n

\n About\u00a0Novavax
<\/b>Novavax, Inc.\u00a0(Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.\u00a0Novavax\u00a0is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu\u2122, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate\u00a0Novavax’ proprietary saponin-based Matrix-M\u2122 adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.<\/p>\n

For more information, visit www.novavax.com<\/a> and connect with us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements
<\/b>Statements herein relating to the future of\u00a0Novavax\u00a0and the ongoing development of its vaccine and adjuvant products are forward-looking statements.\u00a0Novavax\u00a0cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended\u00a0December 31, 2020, as filed with the\u00a0Securities and Exchange Commission\u00a0(SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the\u00a0SEC, available at\u00a0sec.gov<\/a>, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.<\/p>\n

\n Contacts:<\/b>\n <\/p>\n

\n Investors
<\/u>Novavax, Inc.
Erika Schultz<\/span> | 240-268-2022
ir@novavax.com<\/a>\u00a0<\/p>\n

Solebury Trout
Alexandra Roy<\/span> | 617-221-9197
aroy@soleburytrout.com<\/a>\u00a0<\/p>\n

\n Media
<\/u>
\n Laura Keenan<\/span> | 202-709-7521
Alison Chartan<\/span> | 240-720-7804
media@novavax.com<\/a><\/p>\n

\u00a0<\/p>\n

\n

\n
\n \"Novavax
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/novavax-to-participate-in-panel-at-bio-digital-2021-301307002.html<\/a><\/p>\n

SOURCE Novavax, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire GAITHERSBURG, Md., June 7, 2021 \/PRNewswire\/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14. BIO\u00a0Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11 and June 14-18. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion. Panel details are as follows: Date:\u00a0\u00a0 Monday, June 14, 2021 Time:\u00a0\u00a0 3:00 p.m. \u2013 3:45 p.m. Eastern Time (ET) Title:\u00a0\u00a0 Global Pandemic Preparedness \u2013 It Takes a Globe…. Moderator:\u00a0\u00a0\u00a0\u00a0\u00a0 Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization … <\/p>\n

Continue reading “Novavax to Participate in Panel at BIO Digital 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-501465","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire GAITHERSBURG, Md., June 7, 2021 \/PRNewswire\/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14. BIO\u00a0Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11 and June 14-18. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion. Panel details are as follows: Date:\u00a0\u00a0 Monday, June 14, 2021 Time:\u00a0\u00a0 3:00 p.m. \u2013 3:45 p.m. Eastern Time (ET) Title:\u00a0\u00a0 Global Pandemic Preparedness \u2013 It Takes a Globe…. Moderator:\u00a0\u00a0\u00a0\u00a0\u00a0 Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization … Continue reading "Novavax to Participate in Panel at BIO Digital 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-07T20:11:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novavax to Participate in Panel at BIO Digital 2021\",\"datePublished\":\"2021-06-07T20:11:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/\"},\"wordCount\":825,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1527557\\\/Erck.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/\",\"name\":\"Novavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1527557\\\/Erck.jpg\",\"datePublished\":\"2021-06-07T20:11:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1527557\\\/Erck.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1527557\\\/Erck.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-panel-at-bio-digital-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax to Participate in Panel at BIO Digital 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/","og_locale":"en_US","og_type":"article","og_title":"Novavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk","og_description":"PR Newswire GAITHERSBURG, Md., June 7, 2021 \/PRNewswire\/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14. BIO\u00a0Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11 and June 14-18. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion. Panel details are as follows: Date:\u00a0\u00a0 Monday, June 14, 2021 Time:\u00a0\u00a0 3:00 p.m. \u2013 3:45 p.m. Eastern Time (ET) Title:\u00a0\u00a0 Global Pandemic Preparedness \u2013 It Takes a Globe…. Moderator:\u00a0\u00a0\u00a0\u00a0\u00a0 Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization … Continue reading \"Novavax to Participate in Panel at BIO Digital 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-07T20:11:36+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novavax to Participate in Panel at BIO Digital 2021","datePublished":"2021-06-07T20:11:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/"},"wordCount":825,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/","name":"Novavax to Participate in Panel at BIO Digital 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg","datePublished":"2021-06-07T20:11:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1527557\/Erck.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-panel-at-bio-digital-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novavax to Participate in Panel at BIO Digital 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=501465"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501465\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=501465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=501465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=501465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}